Cancer patients can now receive individually personalized treatment thanks to algorithms that account for their own unique factors, according to Leonard M. Fromer, MD, FAAFP, executive medical director of the Group Practice Forum.
Cancer patients can now receive individually personalized treatment thanks to algorithms that account for their own unique factors, according to Leonard M. Fromer, MD, FAAFP, executive medical director of the Group Practice Forum.
Transcript (slightly modified)
How is personalized medicine currently being used to treat patients and in what disease states?
When we talk about personalized or precision medicine, probably the most down-the-road advanced models of what we’re doing with that, as this world changes right in front of our eyes, is oncology. It’s the ability to say that not all patients with a given kind of cancer should be treated the same way. It’s been obvious for years. Some people respond, some don’t, why is that?
If we’re giving them the same agent, and let’s talk about chemotherapy for instance, the answer is it’s their uniqueness. It’s the tumor uniqueness, it’s the staging of the tumor, it’s that own patient’s genetics and the tumor genetics of that person. It’s their other comorbidities, it’s their social environment that they’re living in. It’s all of those things put together.
So in this precision medicine initiative, what we’re first, I think, doing more than anywhere else is, looking at how do we score, if you will, how do we classify a patient with a cancer in their uniqueness. And the way that’s happening, I think, more than anything, is we are developing these nomograms, these systems of care where there’s an alphanumeric code to describe a given patient with a given cancer, and each letter or number in that code describes a uniqueness about that person. From the tumor genetics, to the patient’s own comorbidities, to the other medicines the patients might be taking, to everything that we know about staging of their tumor. All of that gets put into that code, so that we can then make better clinical decisions on how to intervene based on that person’s unique code. That’s what’s happening in cancer.
And there’s a saying in the research behind the development of that and how it’s getting better, is — we used to have research, we still obviously have research, about testing a drug for instance, research around efficacy and safety of a given agent to intervene in everything from cancer patients to heart failure patients to asthma patients to you name it. Anything. We test a drug for efficacy and safety.
The saying now that’s actually as relevant, and maybe more relevant is, we need to start testing the algorithm about how we make the decisions, not just the drug. And that’s our future. That’s precision medicine. Test the algorithm, not the drug. The decision making process. Put something together and then do research to test, does that work to get the patient better triple aim results? Very important, very big news, very different way to look at things.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More